Pearl S. Huang joined Cygnal Therapeutics in January 2019 as president and CEO. She is also an advisor partner at Flagship Pioneering and a member of the boards of Cygnal Therapeutics, KSQ Therapeutics, and Waters Corporation (NYSE:WAT).
Prior to Cygnal, Pearl served as senior vice president and global head of therapeutic modalities at Roche where she oversaw the discovery of biologics, small molecule, and nucleic acid-based therapies. She previously held several other senior roles within the pharmaceutical industry, including vice president and global head of discovery academic partnerships at GSK. In 2010, she co-founded BeiGene and served as chief scientific officer until 2012, developing the company’s initial drug discovery pipeline and moving the company’s first programs into the clinic. From 2006 to 2010, Pearl was vice president, oncology integrator of discovery and early development at Merck, leading 14 early development teams and conducting seven first-in-human trials in one year. Before joining Merck, Pearl led oncology discovery at GSK where she initiated the programs that delivered trametinib and dabrafenib to patients.
Pearl has received multiple awards and recognitions throughout her career. In 2020, she was named to the PharmaVOICE 100, a list of the most inspiring leaders in the life sciences. She has also been honored as one of FiercePharma's 2020 Fiercest Women in Life Sciences and recognized as one of Endpoints News' 2020 Women in Biopharma.
Pearl received her undergraduate degree in life sciences from the Massachusetts Institute of Technology and a Ph.D. in molecular biology from Princeton University.